ProPhase Labs (PRPH) Competitors $0.43 -0.08 (-15.84%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$0.44 +0.01 (+1.73%) As of 09/12/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PRPH vs. VTVT, ICCC, KPTI, ZIVO, PDSB, RLMD, NRXP, QNTM, INMB, and BRNSShould you be buying ProPhase Labs stock or one of its competitors? The main competitors of ProPhase Labs include vTv Therapeutics (VTVT), ImmuCell (ICCC), Karyopharm Therapeutics (KPTI), ZIVO Bioscience (ZIVO), PDS Biotechnology (PDSB), Relmada Therapeutics (RLMD), NRx Pharmaceuticals (NRXP), Quantum Biopharma (QNTM), INmune Bio (INMB), and Barinthus Biotherapeutics (BRNS). These companies are all part of the "pharmaceutical products" industry. ProPhase Labs vs. Its Competitors vTv Therapeutics ImmuCell Karyopharm Therapeutics ZIVO Bioscience PDS Biotechnology Relmada Therapeutics NRx Pharmaceuticals Quantum Biopharma INmune Bio Barinthus Biotherapeutics vTv Therapeutics (NASDAQ:VTVT) and ProPhase Labs (NASDAQ:PRPH) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, dividends, analyst recommendations, risk, institutional ownership, earnings, media sentiment and valuation. Do analysts recommend VTVT or PRPH? vTv Therapeutics presently has a consensus price target of $35.50, suggesting a potential upside of 78.93%. Given vTv Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe vTv Therapeutics is more favorable than ProPhase Labs.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score vTv Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00ProPhase Labs 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has higher earnings and valuation, VTVT or PRPH? vTv Therapeutics has higher earnings, but lower revenue than ProPhase Labs. vTv Therapeutics is trading at a lower price-to-earnings ratio than ProPhase Labs, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatiovTv Therapeutics$17K3,728.75-$18.46M-$3.12-6.36ProPhase Labs$6.77M2.66-$53.36M-$1.26-0.34 Does the media prefer VTVT or PRPH? In the previous week, ProPhase Labs had 6 more articles in the media than vTv Therapeutics. MarketBeat recorded 7 mentions for ProPhase Labs and 1 mentions for vTv Therapeutics. vTv Therapeutics' average media sentiment score of 1.91 beat ProPhase Labs' score of 1.02 indicating that vTv Therapeutics is being referred to more favorably in the media. Company Overall Sentiment vTv Therapeutics Very Positive ProPhase Labs Positive Do institutionals and insiders have more ownership in VTVT or PRPH? 17.5% of vTv Therapeutics shares are held by institutional investors. Comparatively, 9.5% of ProPhase Labs shares are held by institutional investors. 4.2% of vTv Therapeutics shares are held by insiders. Comparatively, 9.6% of ProPhase Labs shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has more risk and volatility, VTVT or PRPH? vTv Therapeutics has a beta of 0.64, indicating that its share price is 36% less volatile than the S&P 500. Comparatively, ProPhase Labs has a beta of -0.78, indicating that its share price is 178% less volatile than the S&P 500. Is VTVT or PRPH more profitable? vTv Therapeutics' return on equity of -179.75% beat ProPhase Labs' return on equity.Company Net Margins Return on Equity Return on Assets vTv TherapeuticsN/A -179.75% -55.91% ProPhase Labs N/A -262.42%-76.48% SummaryvTv Therapeutics beats ProPhase Labs on 10 of the 15 factors compared between the two stocks. Get ProPhase Labs News Delivered to You Automatically Sign up to receive the latest news and ratings for PRPH and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PRPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRPH vs. The Competition Export to ExcelMetricProPhase LabsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$21.40M$2.59B$5.85B$10.14BDividend YieldN/A56.52%5.68%4.60%P/E Ratio-0.3423.8575.4125.98Price / Sales2.66529.66515.81181.13Price / CashN/A171.1637.5660.44Price / Book1.735.3712.156.29Net Income-$53.36M$32.95M$3.29B$271.07M7 Day Performance22.15%1.28%0.74%3.87%1 Month Performance32.41%6.09%4.81%4.88%1 Year Performance-82.31%-2.15%60.57%26.12% ProPhase Labs Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRPHProPhase Labs1.2169 of 5 stars$0.43-15.8%N/A-83.3%$21.40M$6.77M-0.34130News CoveragePositive NewsAnalyst UpgradeShort Interest ↓Gap DownHigh Trading VolumeVTVTvTv Therapeutics2.6222 of 5 stars$18.76+2.5%$35.50+89.2%+35.1%$58.49M$1.02M-6.019Positive NewsGap UpHigh Trading VolumeICCCImmuCell1.3096 of 5 stars$6.41+1.3%N/A+63.1%$57.26M$26.49M33.7470Gap DownKPTIKaryopharm Therapeutics3.8841 of 5 stars$6.25-5.3%$34.00+444.0%-41.6%$57.23M$145.24M-0.43380ZIVOZIVO Bioscience0.3497 of 5 stars$14.85-1.0%N/A-3.7%$56.68M$15.85K-3.0410News CoveragePDSBPDS Biotechnology2.3377 of 5 stars$1.17-2.5%$10.00+754.7%-62.0%$56.43MN/A-1.2720Positive NewsRLMDRelmada Therapeutics4.1272 of 5 stars$1.60-3.0%$5.00+212.5%-51.4%$54.77MN/A-0.7210NRXPNRx Pharmaceuticals3.0224 of 5 stars$2.84+3.3%$34.50+1,114.8%+55.6%$54.48MN/A-1.272Positive NewsAnalyst UpgradeAnalyst RevisionQNTMQuantum Biopharma0.5078 of 5 stars$13.00-7.5%N/A+329.7%$53.63MN/A-0.93N/ANews CoverageGap DownINMBINmune Bio2.9799 of 5 stars$1.81-7.2%$18.40+916.6%-68.5%$51.84M$10K-0.7310Short Interest ↓BRNSBarinthus Biotherapeutics2.989 of 5 stars$1.22-2.0%$3.00+146.9%-14.1%$50.49M$14.97M-0.70107Positive NewsGap Up Related Companies and Tools Related Companies VTVT Competitors ICCC Competitors KPTI Competitors ZIVO Competitors PDSB Competitors RLMD Competitors NRXP Competitors QNTM Competitors INMB Competitors BRNS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PRPH) was last updated on 9/13/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProPhase Labs, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ProPhase Labs With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PRPH Stock Alerts